Efficacy and toxicity of gemcitabine/ dexamethasone / carboplatin versus ESHAP protocol in treatment of relapsed/ refractory Non-Hodgkin’s lymphomas (NHL)
Abbas, F., Abd El kader, M., M.El-wakil, M., Shaban, A. (2022). Efficacy and toxicity of gemcitabine/ dexamethasone / carboplatin versus ESHAP protocol in treatment of relapsed/ refractory Non-Hodgkin’s lymphomas (NHL). EKB Journal Management System, 3(2), 137-143. doi: 10.21608/ejmr.2022.238694
Fatma Ahmad Abbas; Mohamed Sayed Abd El kader; Mohamed Aly M.El-wakil; Ahmad Hassan Shaban. "Efficacy and toxicity of gemcitabine/ dexamethasone / carboplatin versus ESHAP protocol in treatment of relapsed/ refractory Non-Hodgkin’s lymphomas (NHL)". EKB Journal Management System, 3, 2, 2022, 137-143. doi: 10.21608/ejmr.2022.238694
Abbas, F., Abd El kader, M., M.El-wakil, M., Shaban, A. (2022). 'Efficacy and toxicity of gemcitabine/ dexamethasone / carboplatin versus ESHAP protocol in treatment of relapsed/ refractory Non-Hodgkin’s lymphomas (NHL)', EKB Journal Management System, 3(2), pp. 137-143. doi: 10.21608/ejmr.2022.238694
Abbas, F., Abd El kader, M., M.El-wakil, M., Shaban, A. Efficacy and toxicity of gemcitabine/ dexamethasone / carboplatin versus ESHAP protocol in treatment of relapsed/ refractory Non-Hodgkin’s lymphomas (NHL). EKB Journal Management System, 2022; 3(2): 137-143. doi: 10.21608/ejmr.2022.238694

Efficacy and toxicity of gemcitabine/ dexamethasone / carboplatin versus ESHAP protocol in treatment of relapsed/ refractory Non-Hodgkin’s lymphomas (NHL)

Egyptian Journal of Medical Research
Article 9, Volume 3, Issue 2, April 2022, Page 137-143  XML PDF (355.57 K)
Document Type: Original Article
DOI: 10.21608/ejmr.2022.238694
View on SCiNiTO View on SCiNiTO
Authors
Fatma Ahmad Abbas; Mohamed Sayed Abd El kader; Mohamed Aly M.El-wakil; Ahmad Hassan Shaban
Beni-suef university, Faculty of medicine, clinical oncology department.
Abstract
Sensitivitytosalvage chemotherapy is one of the strongest predictors of OS and PFS after high-dose therapy with autologous bone marrow or peripheral blood stem cell transplantation (ABMT) in relapsed or refractory non-Hodgkin’slymphoma. Consequently, efforts have been  focused  on developing salvage chemotherapy protocols  aiming at improving  response rate for this particular group of patients. (6). Response rates to conventional chemotherapy are generally greater than 50%; however, Most NHL patients eventually relapse. Relapse of NHL may occur several months to years after the initial remission; however, the majority of relapses for aggressive patients.
Numerous salvage chemotherapy regimens have been used to treat relapsed or refractory DLBCL.The majority are based on agents that demonstrate non cross resistance to those used in primary therapy. Studies on salvage therapy have generally included all patients with aggressive lymphoma and are not restricted to DLBCtechniques(5). An ideal salvage therapy regimen for use prior to ASCT should have a high response rate, low hematologic, andnonhematologictoxicity.(3)     
Keywords
Relapsed or refractory NHL; salvage chemotherapy regimens; High-dose therapy with Autologous stem cell transplantation (ASCT); Gem /dexa/Carbo; ESHAP; response rate and Toxicity
References
  1. Gisselbrecht C et al.Rituximab maintenance therapy after autologousstem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma. J ClinOncol 2012; 30:4462–4469.   
  2. Jantunen E, et al. EBMT Lymphoma Working Party. Autologous stem cell transplantation in elderly patients (> or = 60 years) with diffuse large B-cell lymphoma: an analysis based on data in the European Blood and Marrow Transplantationregistry. Haematologica. 2008;93(12):1837-42. Volume 14, Issue 3, March 2008, Pages 259–267.
  3. Jorge Labrador et al.as salvage therapy for relapsed or refractory Hodgkin’s lymphoma.  Ann Hematol (2014) 93:1745–1753.
  4. Pfreundschuh M, etal. MabThera International Trial (MInT) Group. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT)Group. Lancet Oncol2011;12(11):1013-1022.
  5. Tara Seshadri et al, Salvage Therapy for Relapsed/Refractory Diffuse Large B Cell Lymphoma,biology of blood and marrow transplantation, Volume 14, Issue 3, March 2008, Pages 259–267.
  6. Vose JM et al : Autologous transplantationfor diffuse aggressivenon-Hodgkin lymphomain first relapse or second remission. Biol Blood MarrowTransplant2004, 10: 116– 127.
  7. Wang WS, et al. ESHAP as salvage therapy for refractory Non-Hodgkin’s lymphoma: Taiwan experience. Jpn J ClinOncol. 1999;29(1):33–7.
  8. Zelenetz AD, Abramson JS, Advani RH, et al. NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin’s lymphomas. J Natl Compr Canc Netw. 2010;8(3):288–334.
 

 

Statistics
Article View: 198
PDF Download: 89